New Periodontitis Treatment Under Investigation

New Periodontitis Treatment Under Investigation

The Stony Brook University School of Dental Medicine and Traverse Biosciences are partnering to evaluate the preclinical safety and effectiveness of the drug TRB-N0224 in the treatment of periodontal diseases. The National Institute of Dental and Craniofacial Research is supporting the project with a $1.3 million grant.

In 2015, Traverse Biosciences signed an exclusive licensing agreement with the Research Foundation for the State University of New York, of which Stony Brook is a part, to develop a drug to treat canine periodontal diseases. The partnership has led to the development of drug candidates that are chemically modified curcumins—substances produced by plants that serve as the active ingredients in the spice turmeric—and designed to treat inflammation. The leading candidate TRB-N0224 will be evaluated for the treatment of periodontal diseases in both companion animals and humans. At the culmination of the investigation, it is hoped that the US Food and Drug Administration will approve TRB-N0224 as a treatment for chronic inflammatory diseases, including periodontitis.

Hygiene Connection E-Newsletter

October 2016